Sanibel Captiva Trust Company Inc. Has $1.15 Million Stock Holdings in Novartis AG (NYSE:NVS)

Sanibel Captiva Trust Company Inc. reduced its position in shares of Novartis AG (NYSE:NVS) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,840 shares of the company’s stock after selling 405 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in Novartis were worth $1,152,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in NVS. Steigerwald Gordon & Koch Inc. lifted its position in Novartis by 4.8% during the third quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock valued at $241,000 after purchasing an additional 95 shares during the last quarter. Centaurus Financial Inc. raised its position in shares of Novartis by 1.7% during the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after buying an additional 98 shares in the last quarter. FLC Capital Advisors lifted its holdings in shares of Novartis by 4.4% during the 3rd quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock worth $272,000 after acquiring an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC grew its position in Novartis by 2.3% in the third quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock worth $509,000 after acquiring an additional 100 shares in the last quarter. Finally, Allen Wealth Management LLC increased its stake in Novartis by 1.8% in the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock valued at $666,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on NVS shares. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating and seven have assigned a hold rating to the stock. Based on data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and a consensus price target of $121.50.

Novartis Stock Down 0.4 %

Shares of Novartis stock opened at $97.51 on Friday. The company’s 50 day moving average price is $100.61 and its 200-day moving average price is $108.99. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The stock has a market capitalization of $199.30 billion, a price-to-earnings ratio of 11.32, a P/E/G ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. The firm had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period in the prior year, the firm posted $1.74 earnings per share. Equities research analysts forecast that Novartis AG will post 7.63 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.